{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 37,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a vertical process flow diagram to represent development stage gates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/12",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.09,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Development Stage Gates",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1579197-c82f-4fca-9731-9c73bb53bfa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Abbrev: RCC: Renal Cell Carcinoma; CPI: Checkpoint Inhibitor; FDA: Food and Drug Administration; MHRA: Medicines and Healthcare products Regulatory Agency; ILAP: Innovative Licensing and Access Pathway. IL-2R: IL-2 receptor; rhIL-2: recombinant human IL-2; IL-2Ra: IL-2R alpha",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fbb899b-1182-4540-9305-c6d68d92a90d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.08,
        "x": 0.86,
        "y": 0.23
      },
      "kind": "image",
      "text": "Nemvaleukin logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b6ef060-4d52-45a1-8a70-98713efbe99e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.13,
        "y": 0.22
      },
      "kind": "list",
      "text": "Novel Design: Fusion protein of IL-2 and IL-2Ra, designed to expand therapeutic benefits while mitigating toxicities; stable and active.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07e6ecf8-9479-45a7-a6e2-0d785a977964",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.82,
        "x": 0.13,
        "y": 0.38
      },
      "kind": "list",
      "text": "Pharmacological PoC: Dose-dependent expansion of NK and CD8+ T cells; minimal non-dose dependent effects on Tregs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12e42de3-038f-440b-8959-284116f5d1db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.82,
        "x": 0.13,
        "y": 0.68
      },
      "kind": "list",
      "text": "Potential Approval and Indication Expansion: Near-term data readouts (PROC, Mucosal Melanoma); focus on new dosing and indications.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cccf05a-f815-4eca-904e-0d6a1df34111",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.13,
        "y": 0.52
      },
      "kind": "list",
      "text": "Clinical Validation: Monotherapy responses in melanoma/RCC; combination with pembrolizumab; IV QDx5 dosing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85aefb7e-baec-4eb9-85fa-b9dda00b4243",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "Nemvaleukin: A Disciplined and Systematic Approach to Developing an Engineered IL-2 Variant",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5380921d-0aa7-4e26-ad09-f022cea8c5a8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "a8880e9b-2313-4d40-af4d-53ca0a262569",
      "evidence": "Vertical stage gate flow diagram",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}